UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer

Annals of oncology, 2018-10, Vol.29, p.viii413-viii413

2018

Volltextzugriff (PDF)

IQGAP1 Promotes Cell Motility and Invasion

The Journal of biological chemistry, 2003-10, Vol.278 (42), p.41237-41245

2003

Volltextzugriff (PDF)

P1446: PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN BCMA‐DIRECTED CAR‐T CELL THERAPY MANUFACTURED USING THE T‐CHARGETM PLATFORM FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)

HemaSphere, 2022-06, Vol.6 (Suppl), p.1329-1330

2022

Volltextzugriff (PDF)

IQGAP1 Is a Component of Cdc42 Signaling to the Cytoskeleton

The Journal of biological chemistry, 2002-07, Vol.277 (27), p.24753-24763

2002

Volltextzugriff (PDF)

Physical and Functional Interaction of Androgen Receptor with Calmodulin in Prostate Cancer Cells

Proceedings of the National Academy of Sciences - PNAS, 2004-01, Vol.101 (2), p.464-469

2004

Volltextzugriff (PDF)

Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing

Nature methods, 2005-06, Vol.2 (6), p.449-454

2005

Volltextzugriff (PDF)

1159PPhase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

201P Phase II study of taminadenant (A2AR antagonist) + spartalizumab (anti PD-1 antibody) in patients with triple-negative breast cancer (TNBC)

Immuno-oncology technology, 2022-12, Vol.16, p.100312, Article 100312

2022

Volltextzugriff (PDF)

B Cell Receptor-induced cAMP-response Element-binding Protein Activation in B Lymphocytes Requires Novel Protein Kinase Cδ

The Journal of biological chemistry, 2004-07, Vol.279 (29), p.30123-30132

2004

Volltextzugriff (PDF)

Identification and characterization of the Cdc42-binding site of IQGAP1

Biochemical and biophysical research communications, 2003-05, Vol.305 (2), p.315-321

2003

Volltextzugriff (PDF)

Antigen receptor–mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth

Blood, 2006-06, Vol.107 (11), p.4458-4465

2006

Volltextzugriff (PDF)

Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Cancer research (Chicago, Ill.), 2021-06, Vol.81 (11), p.3079-3091

2021

Volltextzugriff (PDF)

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002863

2021

Volltextzugriff (PDF)

Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8004-8004

2023

Volltextzugriff (PDF)

Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5560-5560

2018

Volltextzugriff (PDF)

Inhibition of MDM2 promotes anti-tumor responses in p53 wild-type cancer cells through their interaction with the immune and stromal microenvironment

Cancer research (Chicago, Ill.), 2021-01

2021

Volltextzugriff (PDF)

Antigen receptor-mediated changes in glucose metabolism in B lymphocytes : role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth. Commentary

Blood, 2006, Vol.107 (11)

2006

Volltextzugriff (PDF)

Changes In Submersed Macrophytes In Relation To Tidal Storm Surges

Journal of aquatic plant management, 1999-01, Vol.37, p.3-12

1999

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)

Erscheinungsjahr

n.n

Thema

Science & Technology
(12)
Life Sciences & Biomedicine
(11)
Humans
(7)
Animals
(5)
Biochemistry & Molecular Biology
(5)
Oncology
(4)
Cdc42 Gtp-Binding Protein - Metabolism
(3)
Female
(3)
Ras Gtpase-Activating Proteins
(3)
Carrier Proteins - Genetics
(2)
Carrier Proteins - Metabolism
(2)
Cell Line, Tumor
(2)
Immunobiology
(2)
Male
(2)
Mice
(2)
Microscopy, Confocal
(2)
Transfection
(2)
Adult
(1)
Aged
(1)
Amino Acid Sequence
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer

IQGAP1 Promotes Cell Motility and Invasion

P1446: PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN BCMA‐DIRECTED CAR‐T CELL THERAPY MANUFACTURED USING THE T‐CHARGETM PLATFORM FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)

IQGAP1 Is a Component of Cdc42 Signaling to the Cytoskeleton

Physical and Functional Interaction of Androgen Receptor with Calmodulin in Prostate Cancer Cells

Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing

1159PPhase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer

201P Phase II study of taminadenant (A2AR antagonist) + spartalizumab (anti PD-1 antibody) in patients with triple-negative breast cancer (TNBC)

B Cell Receptor-induced cAMP-response Element-binding Protein Activation in B Lymphocytes Requires Novel Protein Kinase Cδ

Identification and characterization of the Cdc42-binding site of IQGAP1

Antigen receptor–mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth

Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced CAR T-Cell Efficacy in Preclinical and Early Clinical Development

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM)

Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers

Inhibition of MDM2 promotes anti-tumor responses in p53 wild-type cancer cells through their interaction with the immune and stromal microenvironment

Antigen receptor-mediated changes in glucose metabolism in B lymphocytes : role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth. Commentary

Changes In Submersed Macrophytes In Relation To Tidal Storm Surges

Suchergebnisse filtern